Background and purpose: Dementia in Parkinson's disease (PD) is common and disabling. Identification of modifiable risk factors for it is essential. Vascular risk factors (VRFs) may be associated with cognitive decline in early PD. Biomarkers that serve as surrogates of the long-term effect of VRFs on PD are needed. To that end, we aimed to quantitate white matter hyperintensities (WMH) in early PD, measure associations with VRFs and examine relationships between WMH and longitudinal cognition. Methods: Participants in the Parkinson's Progression Markers Initiative study (141 patients with PD, 63 healthy controls) with adequate baseline structural brain magnetic resonance imaging data were included. Hypertension and diabetes history, and body mass index were combined to create a vascular risk score. WMH were quantitated via automated methods. Cognition was assessed annually with a comprehensive test battery. Results: In the PD group, vascular risk score was associated with WMH for total brain (b = 0.210; P = 0.021), total white matter (b = 0.214; P = 0.013), frontal (b = 0.220; P = 0.002) and temporal (b = 0.212; P = 0.002) regions. Annual rate of change in global cognition was greater in those with higher vascular risk score (b = À0.040; P = 0.007) and greater WMH (b = À0.029; P = 0.049). Higher temporal WMH burden was associated with great decline over time in verbal memory (b = À0.034; P = 0.031). Conclusions: In early PD, modifiable VRFs are associated with WMH on brain magnetic resonance imaging. Temporal WMH burden predicts decline in verbal memory. WMH may serve as a surrogate marker for the effect of VRFs on cognitive abilities in PD.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder associated with numerous motor and non-motor manifestations. Many symptomatic therapies are available, but treatments for some of the more common and disabling manifestations, including cognitive impairment and dementia [1] , are limited. Several predictors of cognitive decline in PD have been identified [2] [3] [4] [5] . Unfortunately, none of these are modifiable. In the non-PD population, modifiable vascular risk factors (VRFs), such as diabetes, hypertension and obesity, have been associated with cognitive decline [6] . In general, modifiable risk factors may account for onethird of all-cause dementia [7] , making them of great potential relevance in PD. Increasing evidence suggests that VRFs are associated with cognitive impairment in patients with PD of several years duration [8, 9] and even in early disease stages [10, 11] .
Generally, cognitive decline associated with VRFs is thought to be the direct consequence of cerebrovascular disease. The latter can manifest clinically with transient ischaemic attack or stroke, but is more often asymptomatic leading to various changes on structural magnetic resonance imaging (MRI), including cortical infarcts, lacunes and white matter hyperintensities (WMH). The converse is also true: WMH most commonly reflect white matter tissue ischaemia pathologically [12] . The presence of WMH predicts increased risk of dementia in older adults [13] and greater rate of cognitive decline in Alzheimer's disease [12, 14] . WMH are thus being examined as surrogate endpoints for the effect of modifying VRFs in non-PD populations [15] .
Interventions designed to modify VRFs in PD are likely to have the greatest impact in early disease, such as untreated PD without dementia. At this disease stage, any longitudinal changes in cognition are small in magnitude and the impact of any intervention would require long trials with large sample sizes. Thus, biomarkers that can serve as surrogates of the effect of VRFs on cognitive trajectory in PD are needed. We therefore aimed to quantitate WMH in early PD, to measure associations with VRFs and to examine the relationship between WMH and longitudinal changes in cognition. Based on the literature in non-PD populations, we hypothesized that there would be an association between modifiable VRFs and WMH, and that WMH would independently predict change in cognition in early PD.
Methods

Study participants
showing clinically significant abnormality. In addition, HC participants could not have a first-degree relative with PD.
Among the 423 participants with PD and 196 HCs in the PPMI study, 220 underwent MRI with fluidattenuated inversion recovery and T1-weighted MRI sequences. Of those, nine were excluded due to poor image acquisition quality (e.g. poor contrast, significant field inhomogeneity or significant motion) and seven were excluded based on image-processing quality control (e.g. poor WMH lesion and segmentation correspondence). The final sample for the baseline analysis included 141 participants with PD and 63 HCs. A total of 134 participants with PD and 61 HCs underwent at least one follow-up cognitive assessment and were included in longitudinal analysis.
The study was approved by institutional review boards at PPMI sites and written informed consent was obtained. Data used in this analysis were downloaded on 31 October 2016.
Assessments Vascular risk factor ascertainment
During the PPMI screening visit, all medical conditions reported by the patient are recorded in the medical conditions log. Self-reported diabetes and hypertension were ascertained from the log. Use of antihypertensive medications was similarly ascertained from medication logs. The individual abstracting data from the logs (C.D.S.) was blinded to MRI findings.
A vascular risk score (VRS) was generated based on the modified Framingham risk score (mFRS) [22] . The mFRS accounts for age, sex, self-reported hypertension and diabetes, body mass index, measured blood pressure (accounting for blood pressure treatment) and smoking history. Smoking history was not ascertained in the PPMI study, so the mFRS was further modified by excluding smoking history, i.e. VRS = mFRS excluding smoking history. This score thus accounts for the two main VRFs, diabetes and hypertension, that have been associated with cognitive dysfunction in early PD cross-sectionally [9, 10] . This score has several advantages. It applies weights to demographics and acquired risk factors and accounts for antihypertensive treatment. Importantly, unlike other VRF scores, mFRS does not rely on laboratory assessment of lipids. The mFRS has been validated and its association with cardiovascular disease is as strong as the traditional FRS score that includes laboratory measurements [22] .
White matter hyperintensity quantification T1-weighted images were first pre-processed for correction of intensity inhomogeneities and extraction of brain tissue. A registration-based multiatlas segmentation method [23] was applied to parcellate the brain into anatomical regions of interest. WMH were segmented by applying a supervised learning-based multimodal segmentation method (white matter lesion segmentation) [24] on T1-weighted and fluid-attenuated inversion recovery images. Minimum WMH volume was set to 25 mm 3 to ensure ischaemic origin of the detected hyperintense area. Regional WMH volumes were calculated in frontal, temporal, parietal and occipital regions. To visualize the spatial extent of WMH accumulation, individual lesion segmentation maps of each subject were non-linearly aligned to a common template and lesion frequency maps were computed. All WMH calculations were performed using an automated process, blinded to clinical history (including VRFs). Quality control assessments were also performed in a blinded approach.
Statistical analysis
Visual inspection of WMH variables revealed that data were not normally distributed. Therefore, a rootcube transformation was applied.
A detailed description of the statistical analysis approach is included in Data S1.
Briefly, descriptive statistics were used to summarize basic demographics, and parametric and non-parametric tests were applied as appropriate to compare groups and examine for associations among variables.
Logistic regression models were used to examine the relationship between VRS and cognitive categorization for cross-sectional analyses pertaining to baseline cognitive function. Linear regression models were used to examine the relationship between VRS or white matter hyperintensity score (WMHS) and cognitive test score. Age at testing, sex, years of education and disease duration (PD group) were included as covariates for the multivariable models.
For longitudinal analyses, linear mixed-effects models were used to examine the relationship between VRS or WMHS and continuous measures of cognition. Age at testing, sex, years of education, baseline cognitive test score and disease duration (PD group) were included as covariates. Generalized estimating equations examined the relationship of VRS, WMHS and occurrence of MCI on follow-up.
Statistical significance was set at P < 0.05. Analyses were conducted with Stata-13 (StataCorp, College Station, TX, USA).
Results
Modifiable vascular risk factors and white matter hyperintensities in the Parkinson's disease vs. healthy control group Table 1 shows baseline demographics, VRFs and mean values of WMHS (root-transformed) in the PD and HC groups. There were no significant differences in demographics or VRFs. In both groups, regional WMHS was highest in frontal regions. There were no significant differences in global or regional WMHS in the PD vs. HC groups. Frequency maps of segmented WMH for the PD group are shown in Fig. 1 .
Baseline associations between modifiable vascular risk factors, white matter hyperintensities and cognitive function Baseline associations between VRS and demographics, clinical measures and WMHS are shown in Table 2 . VRS was significantly associated with age in both groups. VRS was higher in males than females in the PD (median VRS, 13 vs. 11, respectively; P = 0.007) and HC (median VRS, 14 vs. 11, respectively; P = 0.031) groups. VRS was associated with Movement Disorders Society Unified Parkinson's Disease Rating Scale subscores in the HC but not the PD group. There were no associations in either group between VRS and 15-item Geriatric Depression Scale score.
In the PD group, VRS was associated with total brain and white matter, frontal and temporal WMHS. Only temporal WMHS associated with VRS in the HC group (Table 2) .
Adjusting for covariates, higher VRS was associated with lower Benton Judgment of Line Orientation scores in the HC group (Table S1 ). In the PD group, there were no associations between VRS and cognitive test scores (Table 3 ). In the PD group, VRS was not significantly different in those with versus without MCI (mean VRS, 13.9 vs. 12.0; P = 0.13, respectively).
Adjusting for covariates, there were no significant associations between WMHS in any brain region and cognitive measures in the HC group (Table S1) . However, in the PD group, global, temporal and parietal WMHS were inversely associated with Hopkins Verbal Learning Test-revised-delayed recall score. WMHS in all brain regions except occipital was associated with Hopkins Verbal Learning Test-revised-recognition score (Table 3) . Otherwise, WMHS in any region was not associated with any other cognitive domain nor with presence of MCI. Relationship between baseline modifiable vascular risk factors, white matter hyperintensities and longitudinal changes in cognition
Median duration of follow-up from baseline in the PD and HC groups was 731 and 761 days, respectively. Cognitive categorization for the PD group at each follow-up time point is shown in Table S2 . In the HCs, VRS was inversely associated with annual rate of change in MoCA and Benton Judgment of Line Orientation scores (Table S3 ). In the PD group, VRS was inversely associated with annual rate of change in MoCA score (b = À0.040; P = 0.008), but not any other cognitive test score or occurrence of MCI at any point in the follow-up (Table 4) .
There were no significant associations between WMH measures and longitudinal measures of cognition in the HC group (Table S3) . Global WMHS was inversely associated with annual rate of change in MoCA score with borderline significance (b = À0.029; 95% confidence interval, À0.058 to À0.0001; P = 0.049), as was occipital WMHS (b = À0.041; 95% confidence interval, À0.080 to À0.001; P = 0.043).
Temporal WMHS was inversely associated with annual rate of change in Hopkins Verbal Learning Test-revised-delayed recall score (b =À0.034; 95% confidence interval, À0.065 to À0.003; P = 0.031) ( Table 4) .
Discussion
We found several relevant associations in this cohort of patients with early PD. First, using a composite measure that accounts for VRFs in a weighted manner, we show a significant association between modifiable VRFs and rate of change in a measure of global cognition (MoCA score). Secondly, there was an association between WMH and modifiable VRFs. Thirdly, WMH burden in total white matter, frontal, temporal, and parietal regions associated with measures of verbal memory at baseline, and temporal WMH associated with measures of verbal memory longitudinally.
Interpretation of differences between the PD and HC groups warrants caution given the differences in study inclusion criteria (HCs required a MoCA score > 26 to enter the study). With that in mind, our findings may suggest that individuals with early PD have a susceptibility to the effects of VRF and WMH above what is seen in those without PD, perhaps due to the synergistic effects of the dual pathology. Our findings require replication in PD and non-PD cohorts matched on cognition at baseline. The relationships that we found between VRS and cognitive impairment/decline in the PD group are consistent with an analysis of the PPMI cohort that examined the association of individual VRFs with cognition, not accounting for antihypertensive treatment [10] . The largest study to examine the association between VRFs, cognition and WMH in early PD included 1759 subjects enrolled in the ProBAND cohort [11] . Cognitive function was examined using a single measure of global cognition (MoCA score) and categorized as normal, MCI or dementia. Cognitive dysfunction was associated with both VRFs and WMH burden. In contrast, we did not find an association between VRS and baseline MoCA score. These cross-sectional differences may be explained by several factors. First, the mean age of the ProBAND cohort was 7 years greater than that of the PPMI cohort. Secondly, only a minority of the ProBAND cohort were unmedicated and dopaminergic therapy may mediate effects of various factors on cognitive function [25] . Thirdly, a smaller proportion of individuals in the PPMI study had MCI or dementia at baseline as defined in the ProBAND study [11] . Finally, our smaller sample size may have prevented us from detecting weaker associations in our cohort.
Regarding the longitudinal changes in cognition, we found a significant inverse association between VRS and rate of change in MoCA score. Importantly, to our knowledge, VRFs are the only possible modifiable risk factor for cognitive decline in PD identified to date. If our findings are confirmed in properly designed epidemiologic and interventional studies, the care of individuals with PD may come to incorporate screening and aggressive VRF modification to prevent cognitive decline. In addition, it will be key to examine whether interventions (such as exercise [26] ) that improve vascular cognitive impairment in other patient populations can also improve cognition in PD.
Imaging changes in PD are of interest as objective measures for both disease characterization and as potential endpoints in clinical trials. In the general population, VRFs are associated with significant increases in WMH over time [27] . Thus, WMH could be a surrogate for the long-term effects of VRFs on the brain. If VRFs are indeed a modifiable risk factor for cognitive dysfunction in PD, having an objective measure of their impact as an endpoint to clinical trials could save time and resources required to follow patients longitudinally with cognitive function as an outcome. We found significant, albeit relatively weak, associations between VRS and WMH in our cohort. Other potential contributors to WMH include VRFs that were not measured in the PPMI study (such as smoking and arrhythmia). However, another consideration is that, in PD, WMH could represent pathology unrelated to ischaemic small-vessel pathology, including amyloid angiopathy and/or other components reflecting an underlying neurodegenerative process [28] . Additional studies are needed to determine if WMH is a robust proxy of VRFs in PD and, more importantly, that interventions to reduce WMH in PD have a meaningful clinical impact.
In the non-PD population, WMH are associated with multidomain cognitive impairment including in executive function and delayed memory recall [29] . There are limited studies examining WMH in newly diagnosed PD. Malek et al. [11] utilized a binary measure of white matter disease, reporting worse cognition in those with leukoaraiosis. Two other reports examining WMH in early PD did not find associations between WMH and cognitive function after adjusting for age [30, 31] . However, the relationship between VRS, WMH and cognition has been widely studied in more advanced PD cohorts. In a study comparing patients with PD with and without MCI, the MCI group had a greater prevalence of VRFs and greater WMH burden globally and in frontal, parietal and occipital regions. WMH associated with MCI independent of VRFs [32] . WMH were associated with abnormalities in executive function, memory and language even in those without MCI, and again even after adjusting for VRFs. Other studies examining associations between WMH and cognitive function have reported similar findings of predominant involvement of executive function and attention in PD samples of wide ranges of disease duration [33] . In contrast, our main finding was an association between WMH and impaired verbal memory.
Most studies examining VRFs and cognition in PD have looked at individual VRFs separately. In contrast, we utilized a composite VRF score, which applies weights according to the strength of association between VRFs and cardiovascular disease, accounting for age, sex and antihypertensive treatment. Furthermore, we used a quantitative measure of WMH with regional subscores. These are both seen as major strengths of this study. However, several limitations to this study warrant mention. First, autonomic dysfunction occurs in PD and it is possible that the pathophysiology and consequences of hypertension in early PD may be different from those in the Framingham cohort. However, significant dysautonomia affecting blood pressure is unlikely in early PD. Secondly, VRFs were self-reported and may be underestimated. Thirdly, we could not include smoking in our analysis as smoking history was not obtained in the PPMI study. The association between smoking and cognitive dysfunction is not clear in the PD population. Some studies show worse cognition in patients with PD with a history of smoking [34] , whereas other studies have not found a relationship between smoking and various PD disease manifestations and WMH [32] including cognition [11] . Concerns regarding omission of this VRF in our study are possibly mitigated by the finding that individuals with PD are less likely to smoke compared with the general population [35] . Another VRF not accounted for in the VRS is hyperlipidemia. A cross-sectional analysis in the PPMI cohort did not find an association between hyperlipidemia and cognition [10] , but we cannot exclude an effect longitudinally. However, we otherwise view the lack of requirement for lipid measurements in the mFRS as an advantage allowing easier applicability for in-clinic VRF assessment. Fourthly, although the neuropsychological battery administered in the PPMI study assesses most cognitive domains, a test for language is not administered and it does not allow categorization of cognition at the highest level of confidence (PD-MCI level II) [36] . This may have limited our ability to detect additional relationships between VRF, cognition and WMH. We did not find an association between MCI and VRS or WMH but the relatively small number with MCI and the fluctuation of MCI over time in early PD requires these results to be interpreted with caution. Unfortunately, we were not able to examine the risk of dementia in relation to VRS or WMH in this cohort due to missing data (see Supporting Information, Table S2 ).
The association between modifiable VRFs and cognitive decline in early PD lends cautious optimism to a potential avenue through which to prevent or delay dementia in PD. An objective surrogate marker of the effects of vascular disease on cognition in PD is needed to allow for efficient clinical trials. We have demonstrated that VRS and WMH are correlated in early PD and that WMH is associated with greater rate of decline in measures of verbal memory. Future work will be needed to demonstrate that interventions to treat VRFs in PD prevent increases in WMH and that this has a clinically meaningful impact on course of cognitive decline.
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